COR
Cencora, Inc.
COR has slightly lower modeled downside risk, despite its lower overall score.
LLY
Eli Lilly and Company
LLY has the edge over COR overall, supported by stronger fundamentals and stronger modeled upside.
COR Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Stable | |
| Stable |
COR's profitability is currently healthy, and its revenue, cash flow and balance sheet are stable.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
COR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 18x | $237 | -32% |
| Forward | 18x | $349 | — |
| Fair | 24x | $320 | -8.3% |
| Current | 26x | $349 | — |
| Expensive | 33x | $450 | +29% |
Historical ranges are pointers, not guarantees.
COR has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
COR Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Stable | |
| Stable | |
| Limited | |
| High |
Analysts expect COR's earnings to grow, with its revenue and profitability holding steady.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over COR on the outlook, with more favorable revenue and profitability expectations.
COR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $19.77 | +47% |
| Q2 2026 | $13.47 | +38% |
| Q1 2026 | $13.05 | +51% |
| Q4 2025 | $8.33 | +18% |
| Q3 2025 | $7.96 | +5.7% |
| Q2 2025 | $9.74 | +5.8% |
| Q1 2025 | $8.64 | -5.5% |
| Q4 2024 | $7.05 | -23% |
| Q3 2024 | $7.53 | -12% |
COR earned $13.47 per share over the past year, up 38% from the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.83 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over COR on earnings, with more consistent year-over-year improvement.
COR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $84.8B | +5.1% |
| Q1 2026 | $78.4B | +3.8% |
| Q4 2025 | $85.9B | +5.5% |
| Q3 2025 | $83.7B | +5.9% |
| Q2 2025 | $80.7B | +8.7% |
| Q1 2025 | $75.5B | +10% |
| Q4 2024 | $81.5B | +13% |
| Q3 2024 | $79.1B | +15% |
COR's revenue has grown year over year every quarter since late 2020: $84.8B last quarter, up 5.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 1.3% | +0.2 points |
| Q1 2026 | 1.5% | +0.1 points |
| Q4 2025 | 0.9% | 0 points |
| Q3 2025 | 0% | -0.1 points |
| Q2 2025 | 1.1% | +0.2 points |
| Q1 2025 | 1.4% | +0.6 points |
| Q4 2024 | 0.9% | -0.3 points |
| Q3 2024 | 0.2% | -0.5 points |
COR's operating margin was 1.3% last quarter, about level with the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over COR on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over COR on profitability, with a higher operating margin.
COR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $2.4B | +$2.5B |
| Q1 2026 | $1.2B | -64% |
| Q4 2025 | -$2.4B | +$400.1M |
| Q3 2025 | $2.9B | +252% |
| Q2 2025 | -$74M | -103% |
| Q1 2025 | $3.2B | +$4.2B |
| Q4 2024 | -$2.8B | -448% |
| Q3 2024 | $818.1M | -50% |
COR generated $4.1B in free cash flow over the past year, about four times what it generated the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over COR on cash flow, with more consistent year-over-year improvement.
COR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.7% | -1.4M shares |
| 1 year | -0.7% | -1.3M shares |
| 3 years | -5.1% | -10.4M shares |
| 5 years | -7.2% | -15M shares |
| Available history | -8.4% | -17.9M shares |
COR has the edge over LLY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $1B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | $71,000 |
| Q2 2025 | — |
| Q1 2025 | $50M |
| Q4 2024 | $385.4M |
| Q3 2024 | $505M |
COR spent $1B buying back its own shares over the past year, up 6.4% from the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
COR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 2.2x | Moderate |
| Q1 2026 | 2.7x | Moderate |
| Q4 2025 | 1.7x | Healthy |
| Q3 2025 | 0.9x | Very low |
| Q2 2025 | 1.6x | Healthy |
| Q1 2025 | 1.6x | Healthy |
| Q4 2024 | 1.6x | Healthy |
| Q3 2024 | 0.4x | Very low |
COR's net debt is about 2.2 years of its operating earnings (EBITDA), up from 1.6 years a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY has the edge over COR on leverage, with a lower net debt burden relative to earnings.
COR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 63.7 | Neutral |
| Stochastic | 68.6 | Neutral |
COR's weekly RSI is 64 (neutral) and its Stochastic is 69 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
COR PE vs Healthcare Sector
| Metric | COR | Sector median | Relative |
|---|---|---|---|
| PE | 26x | 26x | 0.3% above |
| PE % | 68 | 29 | 39 pts above |
COR has the edge over LLY on valuation relative to its sector.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
COR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $328.2 | 6.5% above |
| 20 week MA | $319.5 | 9.3% above |
| 50 week MA | $321.3 | 8.7% above |
| 100 week MA | $304.2 | 15% above |
| 200 week MA | $255.0 | 37% above |
COR is in an uptrend: it's above all five of its weekly moving averages, and 37% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
COR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $84.9 | $97.0 | +14% |
| 2021 | $97.0 | $129.5 | +34% |
| 2022 | $129.5 | $170.0 | +31% |
| 2023 | $170.0 | $205.4 | +21% |
| 2024 | $205.4 | $226.9 | +10% |
| 2025 | $226.9 | $341.1 | +50% |
| 2026 YTD | $341.1 | $349.4 | +2.4% |
COR has finished every year since 2020 higher, and it's up 2.4% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over COR on returns for 2026, with the stronger performance.